Jean-Paul Soulillou

This inventor holds 6 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: National Institute of Health and Medical Research, Imtix-Sangstat, Leland Stanford Junior University. Active years: 2001-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jean-Paul Soulillou. Retrieved from https://idiyas.com/inventor/jean-paul-soulillou

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 6 (Patent Applications = 7)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 14)

Average Co-Inventor Count = 3.5

ph-index = 3

Forward Citations = 54(Granted Patents)

Company Filing History:

3 out of 1,853

National Institute of Health and Medical Research

Leland Stanford Junior University

patents

4. 1 out of 30

Ose Immunotherapeutics

where one patent can have more than one assignee

Years Active: 2001-2023

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11725044 - Method for producing polyclonal antibodies with improved complement-dependent cytotoxicity (2023-08-15),

2. 11084871 - Composition with reduced immunogenicity (2021-08-10),

3. 9447182 - Antibodies directed against the alpha chain of IL7 receptor—their use for the preparation of drug candidates (2016-09-20),

4. 8932808 - Methods and compositions for determining a graft tolerant phenotype in a subject (2015-01-13),

5. 7723482 - Anti-CD28 antibody (2010-05-25),

6. 6214342 - Method for increasing mean survival times of transplants with LFA-1-specific antibodies (2001-04-10),

Title: The Innovations of Jean-Paul Soulillou

Introduction

Jean-Paul Soulillou is a notable inventor based in Nantes, France. He has made significant contributions to the field of medical research, particularly in the development of polyclonal antibodies. With a total of six patents to his name, Soulillou's work has had a profound impact on immunology and therapeutic applications.

Latest Patents

One of his latest patents is a method for producing polyclonal antibodies with improved complement-dependent cytotoxicity. This invention relates to polyclonal antibodies directed against at least one non-human biological pathogen or against at least one molecule derived from said pathogen. These antibodies are designed to be devoid of specific antigenic determinants, such as N-glycolneuraminic acid (Neu5Gc) and α-1,3-galactose, enhancing their use as a medicament. Another significant patent is a composition with reduced immunogenicity, which comprises polyclonal antibodies directed against human cells, also lacking the aforementioned antigenic determinants, and its application as a medicament.

Career Highlights

Throughout his career, Jean-Paul Soulillou has worked with esteemed organizations, including the Institut National de la Santé et de la Recherche Médicale and Imtix-Sangstat. His research has focused on advancing the understanding and application of polyclonal antibodies in medical treatments.

Collaborations

Soulillou has collaborated with notable colleagues in his field, including Bernard Vanhove and Sophie Brouard. Their joint efforts have contributed to the advancement of immunological research and the development of innovative therapeutic solutions.

Conclusion

Jean-Paul Soulillou's contributions to the field of immunology through his patents and collaborations highlight his role as a significant inventor. His work continues to influence the development of medical treatments and the understanding of polyclonal antibodies.

Profile summary based on public USPTO records.